Following up on our commentary on global validation for Chinese CPIs:

Presented at #ESMO26: The US randomized ASTRIDE study marks the first bridging trial to validate a Chinese anti-PD-1 CPI (serplulimab) in a US population! 🇺🇸

Key findings vs standard atezolizumab + chemo:
🔹 mOS: 12.4 vs 10.2 mo (HR 0.82)
🔹 24-mo OS: 32.2% vs 17.6%
🔹 Safety: Comparable profiles

A step forward in confirming that data from trials like ASTRUM-005 successfully translates to Western cohorts! 🌍 #ESSCLC #LungCancer #IO